An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough.

Autor:	Abdulqawi R; University of Manchester, Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, Manchester, UK.; King Fahad Specialist Hospital-Dammam, and Dept of Medicine, Alfaisal University, Riyadh, Saudi Arabia.; Manchester University NHS Foundation Trust, Manchester, UK.; These authors contributed equally., Satia I; University of Manchester, Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, Manchester, UK.; McMaster University, Dept of Medicine, Division of Respirology, Hamilton, Canada.; Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, Canada.; These authors contributed equally., Holt KJ; University of Manchester, Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, Manchester, UK.; Manchester University NHS Foundation Trust, Manchester, UK., Dockry R; University of Manchester, Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, Manchester, UK.; Manchester University NHS Foundation Trust, Manchester, UK., Sen S; Manchester University NHS Foundation Trust, Manchester, UK., Smith JA; University of Manchester, Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, Manchester, UK.; Manchester University NHS Foundation Trust, Manchester, UK.
Jazyk:	angličtina
Zdroj:	ERJ open research [ERJ Open Res] 2021 Sep 20; Vol. 7 (3). Date of Electronic Publication: 2021 Sep 20 (Print Publication: 2021).
DOI:	10.1183/23120541.00447-2021
Abstrakt:	Blocking NMDA receptors with memantine in refractory chronic cough patients is poorly tolerated and demonstrates no improvement in cough https://bit.ly/3kgx2g1. Competing Interests: Conflict of interest: R. Abdulqawi reports personal fees from AstraZeneca, Boehringer Ingelheim and Mundipharma outside the submitted work. Conflict of interest: I. Satia reports personal fees from educational talks for GPs from GSK and AstraZeneca, grants and personal fees from Merck Canada, and an ERS Respire 3 Marie Curie Fellowship, outside the submitted work. Conflict of interest: K.J. Holt has nothing to disclose. Conflict of interest: R. Dockry has nothing to disclose. Conflict of interest: S. Sen has nothing to disclose. Conflict of interest: J.A. Smith reports grants and personal fees from GSK, NeRRe Pharmaceuticals, Menlo, Bayer, Boehringer Ingleheim, Axalbion, Afferent and Merck; personal fees from Genentech, Neomed, Bellus, Chiesi, AstraZeneca and Algernon; and nonfinancial support from Vitalograph, all outside the submitted work. In addition, J.A. Smith has a patent (A method for generating output data) licensed. (Copyright ©The authors 2021.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu